Improvement and longterm maintenance of quality of life during treatment with adalimumab in severe rheumatoid arthritis

Journal of Rheumatology

Volumn 34, Issue 12, 2007, Pages 2343-2350

  Mittendorf, Thomas ^a   Dietz, Birgitta ^b   Sterz, Raimund ^b   Kupper, Hartmut ^b   Cifaldi, Mary A ^c   Von Der Schulenburg, Johann Matthias ^a  

^a LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^b ABBOTT GMBH AND CO KG   (Germany)

^c ABBOTT LABORATORIES   (United States)

Author keywords

Biologicals; Cost effectiveness; Fatigue; Quality of life; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB;

ADULT; AGED; ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DRUG EFFECT; FATIGUE; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH SURVEY; HUMAN; LONG TERM CARE; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SHORT FORM 36; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 36849039085     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Kvien T. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 2004;22 Suppl 1:1-12.
2. Kirwan JR, Hewlett SE, Heiberg T, et al. Incorporating the patient perspective into outcome assessment in rheumatoid arthritis: Progress at OMERACT 7. J Rheumatol 2005;32:2250-6.
3. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11.
4. Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. Cochrane Database Syst Rev 2005;3:CD005113.
5. van de Putte L, Rau R, Breedveld F, et al. One year efficacy results of the fully human anti-TNF antibody D2E7 in rheumatoid arthritis [abstract]. Arthritis Rheum 2000;43 Suppl:269.
6. van de Putte LBA, Rau R, Burmester GR, et al. Sustained 5-year efficacy of adalimumab (HUMIRA®) monotherapy in DMARD-refractory rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 2003;48 Suppl:S314.
7. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
8. Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. Long-term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4-year extended study. Ann Rheum Dis 2006;65:753-9.
9. Groessl EJ, Ganiats TG, Sarkin AJ. Sociodemographic differences in quality of life in rheumatoid arthritis. Pharmacoeconomics 2006;24:109-21.
10. Mittendorf T, Greiner W, von der Schulenburg JM. Importance of health related quality of life in RA [German]. Gesundh ökon Qual manag 2004;9:322-8.
11. Garratt A, Schmidt L, Mackintosh A, Fitzpatrick R. Quality of life measurement: bibliographic study of patient assessed health outcome measures. BMJ 2002;324:1417. doi:10.1136/bmj.324.7351.1471.
12. Blumenauer B, Cranney A, Clinch J, Tugwell P. Quality of life in patients with rheumatoid arthritis. Pharmacoeconomics 2003;21:927-40.
13. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93.
14. Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 2005;32:811-9.
15. Ware J, Snow K, Kosinski M, et al. SF-36 Health Survey. Manual and interpretation guide, 2nd ed. Boston: The Health Institute, New England Medical Center; 1997.
16. Brooks R, Rabin R, de Charro F, editors. The measurement and valuation of health status using EQ-5D: A European perspective. London: EuroQol Group; 2003.
17. Furlong W, Feeny D, Torrance G, Barr RD. The Health Utilities Index (HUI) system for assessing health related quality of life in clinical studies. Ann Med 2001;33:375-84.
18. van de Putte LBA, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease-modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16.
19. Mittendorf T, Dietz BM, von der Schulenburg JM, Reitberger U, Cifaldi M, Sterz R. HAQ and FACIT-F are better predictors of societal costs of rheumatoid arthritis than DAS 28 [abstract]. Arthritis Rheum 2006;54 Suppl:S115.
20. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
21. Kosinski M, Zhao S, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;43:1478-87.
22. Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI3): Concepts, measurement properties and applications. Health Qual Life Outcomes 2003;1:54.
23. Picavet HS, Hoeymans N. Health related quality of life in multiple musculoskeletal diseases: SF-36 and EQ-5D in the DMC3 study. Ann Rheum Dis 2004;63:723-9.
24. Roux CH, Guillemin F, Boini S, et al. Impact of musculoskeletal disorders on quality of life: an inception cohort study. Ann Rheum Dis 2005;64:606-11.
25. Dietz BM, van de Putte LBA, Holtbrugge W, et al. Adalimumab (HUMIRA) monotherapy sustains long-term improvements in fatigue in patients with severe rheumatoid arthritis (RA) [abstract]. Ann Rheum Dis 2005;64 Suppl III:579.
26. Dietz BM, van de Putte LBA, Holtbrugge W, et al. Adalimumab (HUMIRA) monotherapy provides sustained long-term improvement in health utility in patients with rheumatoid arthritis (RA) [abstract]. Ann Rheum Dis 2005;64 Suppl III:393.
27. Pollard L, Choy EH, Scott DL. The consequences of rheumatoid arthritis: Quality of life measures in the individual patient. Clin Exp Rheumatol 2005;23 Suppl 39:S43-52.
28. Torrance G, Tugwell P, Amorosi S, Chartash E, Sengupta N. Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate. Rheumatology Oxford 2004;43:712-8.
29. Marra C, Rashidi A, Guh D, et al. Are indirect utility measures reliable and responsive in rheumatoid arthritis patients? Qual Life Res 2005;14:1333-44.
30. Kvien TK, Kaasa S, Smedstad LM. Performance of the Norwegian SF-36 Health Survey in patients with rheumatoid arthritis. II. A comparison of the SF-36 with disease-specific measures. J Clin Epidemiol 1998;51:1077-86.
31. Kavanaugh A. Health economics: Implications for novel antirheumatic therapies. Ann Rheum Dis 2005;64:65-9.
32. Bansback N, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis 2005;64:995-1002.
33. Bansback N, Regier D, Ara R, et al. An overview of economic evaluations for drugs used in rheumatoid arthritis: focus on tumour necrosis factor-alpha antagonists. Drugs 2005;65:473-96.
34. Emery P, Fleischmann RM, Strand V. A summary of adalimumab (HUMIRA) pivotal trial evidence of HAQ disability improvement and the effect of disease duration [abstract]. Ann Rheum Dis 2004;63 Suppl I:265.
35. Wong J. Cost-effectiveness of anti-tumor necrosis factor agents. Clin Exp Rheumatol 2004;22 Suppl 35:S65-70.
36. Michaud K, Wolfe F. Reduced mortality among RA patients treated with anti-TNF therapy and methotrexate [abstract]. Ann Rheum Dis 2005;64 Suppl III:87.